Mutant Kras (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is observed in more than 20% of non-small-cell lung cancers; however, no effective Kras target therapy is available at present. The Kras DNA vaccine may represent as a novel immunotherapeutic agent in lung cancer. In this study, we investigated the antitumor efficacy of the Kras DNA vaccine in a genetically engineered inducible mouse lung tumor model driven by Kras G12D . Lung tumors were induced by doxycycline, and the therapeutic effects of Kras DNA vaccine were evaluated with delivery of Kras G12D plasmids. Mutant Kras G12D DNA vaccine significantly decreased the tumor nodules. A dominant-negative mutant Kras G12D N17, devoid of oncogenic activity, achieved similar therapeutic effects. The T-helper 1 immune response was enhanced in mice treated with Kras DNA vaccine. Splenocytes from mice receiving Kras DNA vaccine presented an antigen-specific response by treatment with peptides of Kras but not Hras or OVA. The number of tumor-infiltrating CD8 + T cells increased after Kras vaccination. In contrast, Kras DNA vaccine was not effective in the lung tumor in transgenic mice, which was induced by mutant L858R epidermal growth factor receptor. Overall, these results indicate that Kras DNA vaccine produces an effective antitumor response in transgenic mice, and may be useful in treating lung cancer-carrying Ras mutation.
INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality in the world. 1 Two major forms of lung cancer are non-small-cell lung cancer (NSCLC) and small-cell lung cancer. About 80% of lung cancers are NSCLC, and~55% of NSCLCs are adenocarcinoma. 2, 3 A number of genetic and epigenetic abnormalities are acquired during the development of lung cancer. 4 Among the oncogenes in NSCLC, mutations on the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras) are most frequently observed (20-30%). 5, 6 Although normal Kras performs a growth-promoting function in normal tissue under strict regulation, the mutation of Kras (usually in codons 12, 13 and 61) results in constitutive activation of signaling and is required in the development of many cancers, including leukemia, pancreatic cancer, colorectal cancer and lung cancer. 7 Current therapeutic approaches on cancer-carrying mutant Kras are mainly targeted on downstream signaling, including MEK inhibitors and Braf inhibitors. [8] [9] [10] Currently, the direct-targeting therapeutic approach on Ras is to inhibit the translocation of Kras to the plasma membrane, including farnesyltransferase inhibitors and geranylgeranyltransferase inhibitors. 11, 12 Unfortunately, the therapeutic efficiency of these selected RAS-directed therapies has not been demonstrated in clinical trials. 13, 14 Cancer immunotherapy, triggering an immune response targeting tumor-associated antigen in cancer cells, may provide an alternative complementary therapeutic approach. Mutant Kras peptides have been developed as antitumor drugs by inducing antigen-specific cytotoxic T lymphocyte (CTL) response in vitro. 15 Dendritic cells (DCs) presenting mutant Kras are effective in inducing antigen-specific CTL activity, and function against mouse pancreatic tumor models. 16 Treatment with a 17-mer peptide of Kras plus T-helper (Th) epitopes exhibited a specific CTL response in vivo. 17 The Kraspeptide vaccine was found to be safe but exhibited weak producible immunogenicity, and the efficacy was not proven in cancer patients with pancreatic adenocarcinoma. 18 In addition to protein vaccine, DNA vaccines are able to elicit antitumor response via expressing encoding tumor-associated antigens 19 and offer several advantages, including ease of development, production and persistent expression of the immunogen. 20 Humoral and cellular immune response can also be triggered through various delivery approaches, including intramuscular (IM) injection, electroporation and gene-gun (GG) intradermal bombardment. 21, 22 Previous studies indicated that administering a DNA vaccine via a GG mainly delivers the vaccine into Langerhans cells and DCs in the epidermis. These cells are members of antigen-presenting cells and can be processed into antigen peptides and presented to the cell surface to boost antigen-specific immune responses in lymphoid organs and against tumor cells. [23] [24] [25] The therapeutic efficiency of epidermal growth factor receptor (EGFR) and Her2/neu DNA vaccines has been evaluated in subcutaneous lung and bladder tumor models 26, 27 by enhancing immunogenicity against cancer cells.
However, there is no study that has addressed the Kras-targeted immunotherapy in transgenic animals with lung tumor until now.
To study the molecular mechanisms and treatment of lung cancer, several preclinical lung tumor models have been developed to investigate therapeutic drugs, including transplantable xenograft mouse models and genetically engineered mouse models. It takes less time to evaluate the therapeutic effect in the transplantable models owing to rapid tumor growth; however, the tumor microenvironment/immunity and faster tumor growth do not represent a best model for human cancer. 28 In contrast, genetically engineered mouse models of tumors are grown within an intact host-immune system 29 and present with progressive tumorigenesis of spontaneous tumors, 30, 31 which are more similar to the human cancer when compared with transplantable xenograft mouse models. Several murine transgenic lung cancer models have been developed to investigate the pathogenesis and treatment. A classic bi-transgenic inducible system, CCSP-rtTA/TetOp-K-Ras4G12D, spontaneously develops adenocarcinomas after the administration of doxycycline. The pathology of tumor in the bi-transgenic mice model mimics the neoplastic stage of human NSCLC, and the model is appropriate for evaluating the antitumor efficacy of immune-related therapeutic approaches. As the efficacy of Kras DNA vaccine has not been evaluated in the transgenic animal tumor model, we investigated the therapeutic effects of Kras DNA vaccines in transgenic mice expressing lungspecific Kras G12D . In this study, we found that physical delivery of the mutant Kras DNA plasmid by IM and GG injection markedly boosted the Th type 1 (Th1) immune response and induced antitumor effects in a Kras4b G12D transgenic mouse model.
RESULTS

Kras
G12D DNA vaccine decreased the number of lung tumor nodules in Kras G12D transgenic mice
To investigate the therapeutic effects of Kras G12D DNA vaccine in genetically engineered mouse models of lung cancer, lung tumors of TetO-Kras4b G12D /Scgb1a1-rtTA bi-transgenic mice were induced by the administration of doxycycline for 14 weeks. The point mutation of mouse Kras occurred in the 12th amino acid from glycine (G) to aspartic acid (D). Mice were inoculated with the Kras G12D DNA by GG and/or IM injection (Figure 1a ). At 28 weeks, bi-transgenic mice were killed to evaluate the therapeutic effects of the mutant Kras plasmid by counting the lung tumor nodules. The expression of the Kras G12D plasmid was confirmed with western blot analysis in 293T cells (Figure 1b) . Since administration routes affect the immune responses, 32, 33 we evaluated the antitumor efficacy of Kras DNA vaccine via IM injection or GG delivery. The therapeutic effects were minimal when the mice received Kras DNA vaccine administered by either GG or IM (Figures 1c and d) . Next, we combined the IM injection and GG delivery of Kras DNA vaccine to optimize the therapeutic effects. Mice receiving a combination delivery of Kras G12D DNA vaccine had fewer tumor nodules in the lung than mice receiving the pcDNA3.1 vector, and the control mice (Figures 1e and f) . Taken together, the results demonstrated that the Kras G12D DNA vaccine produced stronger antitumor effects in the spontaneous mouse lung tumor model driven by mutant Kras G12D .
Kras G12D N17 produced an antitumor effect in Kras G12D bi-transgenic mice As the activated Kras G12D is carcinogenic, we further eliminated its activity by a mutation converting the 17th amino acid to asparagine (N), and named the plasmid Kras G12D N17. 34 The expression of Kras G12D N17 DNA vaccine was confirmed in 293T cells and murine bladder tumor cells (MBT-2) by western blotting (Figure 2a and Supplementary Figure S1 ). Inactivation of Ras activity was demonstrated by the loss of phospho-ERK, the downstream ERK activity (Figure 2a) . Following the therapeutic protocol in Figure 1a , Kras G12D bi-transgenic mice were immunized with Kras G12D N17 by skin administration (GG) and IM injection. Bitransgenic mice receiving Kras G12D N17 DNA plasmid had fewer tumors in the lung compared with control bi-transgenic mice (Figure 2b ). The Kras G12D N17 DNA vaccine exhibited similar therapeutic effect as that induced by Kras G12D DNA vaccine (Figure 2c ). These results demonstrate that both inactive and active mutant Kras DNA vaccines have prominent antitumor efficacy in a Kras G12D lung cancer transgenic model. To determine the specificity of Kras DNA vaccine on the tumor expressing mutant Kras, we examined the therapeutic efficacy of Kras G12D N17 DNA vaccine in another inducible lung cancer model driven by mutant EGFR L858R . 35 Kras DNA vaccine did not produce antitumor response in EGFR L858R bi-transgenic mice (Supplementary Figure S2) . These results indicated that Kras DNA vaccine induced therapeutic effects that were specific to the tumor expressing mutant Kras. To further clarify whether the antibody response was involved in the antitumor effects induced by Kras DNA vaccine, we examined anti-Kras G12D antibody titer in the sera from the mice receiving Kras DNA vaccine. The titer of anti-Kras G12D antibody was examined on the plate coating with 17-mer Kras G12D peptides with enzymelinked immunosorbent assay. The anti-Kras G12D antibodies were detected after doxycycline induction of Kras G12D protein expression. However, there was no statistical difference in anti-Kras G12D IgG1, anti-Kras G12D IgG2a and anti-Kras G12D IgA levels between the control group and the vaccinated group (Supplementary Figures  S3a and c) . Overall, these data suggested that the humoral immunity was not correlated with the therapeutic efficacy of Kras DNA vaccine. The cellular immune response may have a major role in the therapeutic effects of Kras DNA vaccine. Double delivery of Kras DNA vaccine displayed stronger immunologic activity in the transgenic lung tumor model Our data demonstrated that the Kras G12D N17 DNA vaccine elicited effective antitumor effects through the combination of IM and GG injections (Figures 1e and f). Individual treatment with the Kras DNA vaccine via IM injection or GG administration did not provide sufficient therapeutic efficiency in bi-transgenic lung cancer mouse models (Figures 1c and d) . We therefore compared the immune response that was triggered by the administration of the Kras DNA vaccine with different delivery methods. The expression of Th1-related cytokines IFN-γ and IL-12 RNA was not enhanced in IM or GG groups, whereas their expression was significantly elevated in the combined group (Figures 4a and b) . The expression of IL-4 increased fourfold in the IM plus GG group and 2.7-fold in the IM group compared with the GG group or the control group (Figure 4c ). In contrast, IL-10 expression in mice receiving the vaccine via GG injection was the highest among all groups, but with no significant difference (Figure 4d ). To examine the cytokine associated with inflammatory response, we examined the mRNA levels of tumor necrosis factor-α mRNA in mice vaccinated with the Kras DNA plasmid. No significant change in tumor necrosis factor-α mRNA was observed in all groups (Figure 4e ). We then evaluated the lung-infiltrating immune cells after vaccination. Lungs were harvested from bi-transgenic mice with each treatment, and the population of CD8 + T cells and CD4 + T cells was examined with flow cytometry. The frequency of TetO-Kras4b G12D /Scgb1a1-rtTA bi-transgenic mice were fed 400 mg l − 1 doxycycline starting at 6 weeks of age. Fourteen weeks after induction, the bi-transgenic mice were inoculated with pcDNA3.1( − ) (vector control) and Kras DNA vaccine via skin delivery with GG and/or IM injection at 5-day intervals for a total of 10 times. Two weeks after the tenth vaccination, mice were killed to evaluate the therapeutic effects of the DNA vaccine. 
lung-infiltrated CD4
+ T cells remained in a similar range in the four experimental groups (Figures 5a and b) . Lung-infiltrated CD8 + T cells were enhanced 3.8-fold in the GG plus IM group, but no significant elevation was observed in the GG or IM groups of mice (Figures 5a and c) . Altogether, treatment with Kras DNA vaccine through combined delivery (IM plus GG) enhanced the immune response, and elicited potent antitumor effects in a spontaneous mouse lung tumor model driven by Kras4b G12D .
DISCUSSION NSCLC patients with the Kras mutation have significantly shorter overall survival regardless of the stage of NSCLC. 6,37-39 Additionally, NSCLC patients with Kras mutations are resistant to the EGFRtargeting treatments, such as Gefitinib and Erlotinib. [40] [41] [42] The benefits of EGFR tyrosine kinase inhibitors are limited because mutant Kras constitutively activated EGFR downstream pathways. 8 On the other hand, Kras-targeted immunotherapy may offer an alternative therapy for these patients. Our study supports the notion that it is feasible to use immunotherapy on NSCLC patients with Kras mutations. The inactive Kras DNA vaccine significantly delayed the formation of lung tumor carrying Kras in the transgenic mice. The Th1 cytokine was elevated and may be responsible for the tumor inhibition by Kras DNA vaccine. It was interesting to note that the other organs were not grossly affected by the Kras DNA vaccine, which may be mainly because of the very low expression of Kras in normal organ.
Activating mutant Kras was observed in about 20-40% of NSCLCs and was associated with poor prognosis; over 80% of these mutations occurred at codon 12 (G12C, 39%; G12V, 21.8%; G12D, 15.6%). 43, 44 It indicates that there are approximately 45 000 NSCLC patients with Kras G12D mutation in 1.3 million new cases of NSCLC worldwide each year. 45 The Kras-targeted therapy may benefit a lot of patients. On the other hand, the abnormal EML4-ALK fusion gene was identified in only 5% of NSCLC patients. 46 Cancer therapy with the specific inhibitor, crizotinib, for ALKpositive lung cancer therapy is one of the most important and encouraging finding in recent years. Moreover, the therapeutic efficiency of Kras vaccines targeting each single mutation, such as G12, G13 or Q61, has been validated in other types of cancers. 15, 18, 47 It suggests that the Kras DNA vaccine developed here may be useful in other types of cancers. Taken together, the therapeutic potential of Kras DNA vaccine is important for cancer patients carrying this mutation.
The mutations on Kras oncogene were observed in approximately 90% of pancreatic cancers, 35-40% of colorectal cancer and some esophageal carcinoma. Anti-Kras antibodies were detectable in 23% esophageal carcinoma patients (19 of 84); nevertheless, there was no association between the production of anti-Kras autoantibody and either response to chemoradiotherapy or survival. 48 IgA antibodies against mutant Kras protein were detected in 32% (51 of 160) of colon cancer patients, but only in 2.5% (1 of 40) of normal individuals. 49 Similarly, the antibody reactivity was not correlated with tumor stage or lymph node metastasis. These evidences suggest that cancer patients with Kras mutation do generate the anti-Kras autoantibodies, but the presence of antibody may not have a correlation with disease progression. On the other hand, CTL response to mutant Kras can be induced by Kras-peptide vaccines in patients with several types of cancers, and the presence of CTL is associated with longer survival. 47 Part of pancreatic and colorectal cancer patients immunized with Kras-peptide vaccines may have higher mRNA level of IFN-γ and more positive outcome in overall survival in a pilot study. 50 Furthermore, mutant Kras peptides can elicit antigen-specific CTL response in NSCLC patients with mutant Kras. 51 Overall, anti-Kras CTL response may have a clinical benefit in lung cancer with Kras mutation.
Our results indicated that Kras DNA vaccine inhibited progression of lung tumors with mutant Kras G12D , but not lung tumors with mutant EGFR L858R . Therefore, the antitumor response induced by Kras DNA vaccine is unlikely due to non-antigen-specific immunity. 52 Additionally, we observed that the splenocytes of mice treated with Kras vaccine had higher IFN-γ, IL-4 and IL-12 expression. During the analysis of cellular immunity, the mixture of splenocytes was used in the experiments. The splenocytes were not separated into CD8 T cells and other populations of splenocytes. The increase in IFN-γ is the indication for the cytotoxicity of CD8 T splenocytes. It was interesting to note that IL-12 was enhanced during peptide restimulation. IFN-γ is known to stimulate the monocytes and macrophages to secrete IL-12. 53, 54 Therefore, the increase in IL-12 may be due to the IFN-γ secreted by activated CD8 T cells in the splenocytes. IL-4 expression was increased by up stimulation of the Kras G12D peptide, which may be an indication for altered immune response. 55 Hence, the interaction of these cytokines in splenocytes may provide a suitable immune interaction for generating immunogenicity to cancer cells in our animal model. On the other hand, IL-12 has a significant role in priming IFN-γ-producing Th1 cells, whereas IL-4 promotes naive T cells into Th2 cells. A current study showed that the antibodybased target delivery of cytokines, IL-4 and IL-12, exhibited additive anticancer effects despite that these cytokine display opposite activity in mediating T-cell polarization. 56 The increased In the genetically engineered mouse model of lung cancer, either IM injection or GG administration of Kras DNA vaccine did not induce sufficient antitumor immunity by itself. However, combination delivery of Kras G12D N17 DNA vaccine via intracellular injection and GG administration effectively triggered an effective antitumor response and strong cellular immune response against lung tumor cells. IM treatment with the plasmid DNA vaccine elicits an antigen-specific Th1-type immune response. 52, 57 The cross-priming mechanism has a central role in the antigen-specific immune response generated by DNA vaccine via IM injection. Antigen uptake by DCs, expressed and released from myocytes, leads to the priming of CD8 + CTL after immunization. The DCs driven from circulating monocytes are rapidly recruited through CCR6/CCL20-dependent mechanism and are responsible for the cross-priming of CD8 + CTL after skin immunization. 58 On the other hand, GG bombardment with DNA plasmid mainly targets on two populations of DCs, that is, epidermis Langerhans cells and interstitial DCs. Naked plasmid delivery via GG can be transferred into CD11c + DCs directly to the epidermis, and those immunized by DCs migrated to the draining lymph nodes for priming and stimulating antigen-specific T cells. 21, 59 Moreover, Ito et al. 32 showed that intradermal injection of EGFP DNA plasmid elicited higher CTL and antibody responses than IM injection in the first week, but declined rapidly. Interestingly, the immune activity induced by IM injection maintains at a similar DNA vaccine effectively induced an antitumor response in xenograft mouse models with subcutaneous 26, 27 and metastatic tumor. 60 The TetO-Kras4b G12D /Scgb1a1 bi-transgenic mice displayed the progressive tumorigenesis of spontaneous tumor and intact immune system, and were suitable for evaluating the immunotherapy. After treatment with doxycycline for 3 months, the lung epithelial cell of bi-transgenic mice progress from hyperplasia to adenocarcinomas, which showed similar histology to human lung cancer. To perform the experiment in a therapeutic model on the established adenocarcinomas, we started inoculation of Kras DNA vaccine inoculation 14 weeks after induction by doxycycline. To our best knowledge, this is the first report that Kras DNA vaccine functions as an effective therapeutic agent against lung tumor in an inducible bi-transgenic Kras mice.
The major concern for the safety is whether DNA vaccine may integrate into the genome and result in enhancing the risk of oncogenesis. A lot of phase I clinical trials on the DNA vaccine have been performed, and the results indicated that naked DNA vaccine in general is safe and well tolerated. 61, 62 The immune tolerance is generally observed in autologous DNA vaccination. Our previous work on neu DNA vaccine has shown that both xenogenic and autologous neu DNA vaccine exerted antitumor effects, but the xenogenic vaccine was more efficient than the autologous vaccine while delivering via GG. However, autologous DNA vaccine could be as effective as xenogenic DNA vaccine by altering the administration route. 63 In this study, rat Kras
G12D
protein is specifically induced in bi-transgenic mice after doxycycline induction. The expression of mutant Kras protein was very low before induction, thereby the immune tolerance may be minimal in the therapeutic phase of DNA vaccine. Further improvement on breaking immune tolerance may be achieved by using xenogenic Kras and electroporation, similar to that observed in mutant p53. 64 Immunologic adjuvant working on CD40 or creation of a fusion protein may provide another approach to circumvent immune tolerance in human clinical trial. 65, 66 In summary, we demonstrated that inactive mutant Kras G12D N17 DNA vaccine produced significant therapeutic responses against lung adenocarcinoma via combinatory IM and GG delivery in a spontaneous mouse lung tumor model driven by Kras G12D . As there is no effective therapeutics against Kras-carrying cancer, our results suggest that Kras DNA vaccine may be used as a therapeutic agent for lung cancer in the future.
MATERIALS AND METHODS
Plasmid construction and preparation of the DNA vaccine Full-length (amino acids 1-188) wild-type murine Kras was amplified from B16F10 cell messenger RNA and was inserted into pcDNA3.1(− ) vector (Invitrogen, Carlsbad, CA, USA). The primers used for construction were: 5′-GAACACCTCGAGATGACTGAGTATAAACTTGTG-3′ (forward) and 5′-CAGT ATGATATCCTACATAACTGTACACCTTGT-3′ (reverse). PCR products were isolated and digested with XhoI and EcoR V. Kras G12D was generated by using site-directed mutagenesis (QuikChange Site-Directed Mutagenesis Kit; Stratagene, Garden Grove, CA, USA). The primers used were: 5′-G TTGGAGCTGATGGCGTAGGCAAGAGCGCC-3′ (forward) and 5′-GGCGCT CTTGCCTACGCCATCAGCTCCAAC-3′ (reverse). Primers used of Kras G12D N17 were 5′-GGCGTAGGCAAGAACGCCTTGACGATACAG3′ (forward) and 5′-C TGTATCGTCAAGGCGTTCTTGCCTACGCC-3′ (reverse). All plasmid DNAs were prepared using the EndoFree Qiagen Plasmid Mega Kit (Qiagen, Montreal, QC, Canada).
Western blot analysis
The following antibodies were used in western blotting: anti-Kras (F234) (sc-30; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-tubulin (CD66; Oncogene Science, Manhasset, NY, USA), anti-β-actin (clone mab1501; Chemicon, Temecula, CA, USA), anti-p44/42 MAPK (T202/Y204) (D13.14.4E; Cell Signaling Technology, Denvers, MA, USA) and anti-44/42 MAPK (ERK1/2) (137F5; Cell Signaling Technology). The 293T cells were transfected with 1 μg of each plasmid to examine the expression efficiency.
After 24 h, cell lysates were prepared by treating cells with RIPA lysis buffer (0.22 M NaCl, 0.38 M Tris-HCl, pH 7.5, 0.25% sodium deoxycholate, and 1% IGEPAL-630). Protein concentration was measured using the Micro BCA Protein Assay Reagent Kit (Pierce, Rockford, IL, USA). The polyvinylidene fluoride membranes were incubated overnight at 4°C with the primary antibody in Tween-Tris-buffered saline containing 1% bovine serum albumin. The secondary antibody was subsequently incubated with the membranes for 1 h at room temperature, and the membranes were then washed extensively for 30 min with Tween-Tris-buffered saline at room temperature. The blots were probed with the ECL Western Blot Detection System (Millipore, Billerica, MA, USA) and visualized with the BioSpectrum AC Imaging System (UVP, Upland, CA, USA) according to the manufacturer's instructions.
Bi-transgenic mice
TetO-Kras4b G12D /Scgb1a1-rtTA bi-transgenic mice were provided from the laboratory of Jan-Jong Hung of National Cheng Kung University (Tainan, Taiwan) and maintained at the National Laboratory Animal Center in Taiwan. FVB.Cg-Tg(Scgb1a1-rtTA)1Jaw/J, FVB/N-Tg(tetO-Kras2)12Hev/J and B6.Cg-Tg(Scgb1a1-rtTA) -1Jaw/J transgenic lines were acquired from the Jackson Laboratory (Bar Harbor, ME, USA). B6;CBA-Tg(tetO-EGFR*L858R) 56Hev was acquired from the National Institutes of Health (Bethesda, MD, USA). After genotyping, 6-week-old bi-transgenic mice were treated with doxycycline (0.4 g ml −1 ) in drinking water to induce tumor formation until being killed. 67 For therapeutic experiments, TetO-Kras4b G12D /Scgb1a1-rtTA bi-transgenic mice were treated with DNA vaccine after 14 weeks of tumor induction; TetO-EGFR*L858R/Scgb1a1-rtTA bi-transgenic mice were treatment with DNA vaccine after 8 weeks of tumor induction. All protocols in this study involving mice were approved by the Animal Welfare Committee at National Cheng Kung University, Tainan City, Taiwan.
Measurement of the therapeutic efficacy of the DNA vaccine Plasmid DNA was administered to bi-transgenic mice in the abdominal area via GG injection (10 μg DNA plasmid in 20 μl of water) or in the leg via IM injection (100 μg DNA plasmid in 100 μl of saline). 21, 27 For combing delivery of Kras DNA vaccine, 10 μg DNA plasmid and 100 μg DNA plasmid were administered into the bi-transgenic mice via GG and IM injection, respectively. The injection was performed 14 weeks after tumor induction at 5-day intervals for a total of 10 times. Administration was performed using a low-pressure GG (BioWare Technologies Co. Ltd, Taipei, Taiwan) with 50 psi of helium gas pressure. Mice were killed at 28 weeks. Lungs excised from bi-transgenic mice were stained with India ink (BD Bioscience, Sparks, MD, USA) and fixed in Fekete's solution (100 ml of 70% alcohol, 10 ml formalin and 5 ml glacial acetic acid) at room temperature. Lung tumor nodules were counted to evaluate therapeutic effects.
Real-time PCR
To explore the immune mechanism induced by Kras DNA vaccine, splenocytes were harvested from bi-transgenic mice 2 days after the third vaccination and incubated with peptides (1 μg ml − 1 in 1 × 10 6 cells in a 6-cm culture dish) for 24 h. The peptide sequences used were as follows: Kras , LRKLNPPDE; and OVA 257-264 , SIINFEKL. Total RNA was extracted from splenocytes by using TRIzol (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI, USA). Hypoxanthine-guanine phosphoribosyltransferase, IL-12p40, IFN-γ, IL-10 and IL-4 primer sequences for real-time PCR were used as previously described 60 (Supplementary Table S1 ). Hypoxanthine-guanine phosphoribosyltransferase served as an internal control. Real-time PCR was performed on an Applied Biosystems 7900HT Real-Time PCR Instrument (Applied Biosystems, Foster City, CA, USA) using FastStart Universal SYBR Green I Master Mix (Roche Diagnostics, Mannheim, Germany). The cycling conditions were 10 min at 95°C and 45 cycles at 95°C for 15 s and 60°C for 60 s.
Flow cytometry analysis
Splenocytes were collected from the spleen of mice 2 days after the third vaccination with the Kras DNA vaccine. Splenocytes were filtered through a 0.7-μm cell strainer (BD Pharmingen, San Diego, CA, USA) and stained with fluorescein isothiocyanate-conjugated anti-CD8 (clone 53-6.7; BD Pharmingen) and phycoerythrin-conjugated anti-IFN-γ (BD Pharmingen) antibodies. BD Pharmingen Transcription Factor Buffer Set (BD Pharmingen) was used for intracellular staining of IFN-γ. To analyze the lung-infiltrating immune cells, lung tissues were dilacerated and enzyme digested for signal-cell suspension (1 mg ml − 1 collagenase A (Roche Diagnostics, Indianapolis, IN, USA); 100 IU ml − 1 type I DNase (Sigma-Aldrich, St Louis, MO, USA), for 1 h at 37°C in 5% CO 2 ). Suspension cells were stained with phycoerythrin-conjugated anti-CD8 (clone 53-6.7; BD Pharmingen) and fluorescein isothiocyanate-conjugated anti-CD4 (clone GK1. Enzyme-linked immunosorbent assay to detect the anti-Kras G12D antibody in the serum
The protocol followed the previous study 27 and the BioLegend enzymelinked immunosorbent assay sets (BioLegend, San Diego, CA, USA) were used with modification. The coating buffer (cat. no. 79008), wash buffer (cat. no. 421601), assay diluent (cat. no. 78888) and substrate solution F (cat. no. 79057) were purchased from BioLegend Company. A week after the last vaccination, sera were collected from blood samples of mice with centrifuge at 1000g for 20 min. The 96-well plates were coated with recombinant 17-mer Kras G12D peptide (4 μg ml 
Statistical analyses
Statistical analyses of the tumor nodules and mRNA expression levels were performed by using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). Student's t-test was used to analyze the difference between groups. P-values o0.05 were considered significant.
